IRON · Disc Medicine, Inc.
$74.51
-0.69% last session
End-of-day data · close of 2026-10-23
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-10.8
Dividend yield
0.0%
Beta
2.11
Avg volume
1M
Employees
0K
Daily Change %
-0.69%
5 Days Change
32.00%
10 Days Change
32.56%
30 Days Change
13.53%
60 Days Change
-7.30%
Month to Day Change
17.95%
Year to Day Change
-5.52%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IRON
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-20
Latest call per bank · past 12 months
Morgan Stanley
Overweight$92.00
+23.5% vs priceWells Fargo
Overweight$124
+66.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Morgan Stanley | Maintains | Overweight | $90.00 → $92.00 |
| 2026-10-20 | Truist Securities | Maintains | Buy | $83.00 → $115 |
| 2026-10-20 | Wells Fargo | Maintains | Overweight | $86.00 → $124 |
| 2026-10-20 | Wedbush | Maintains | Outperform | $100 → $110 |
| 2026-10-19 | BMO Capital | Maintains | Outperform | $100 → $120 |
| 2026-10-19 | Cantor Fitzgerald | Maintains | Overweight | $125 → $170 |
| 2026-09-16 | Wells Fargo | Maintains | Overweight | $79.00 → $86.00 |
| 2026-09-10 | Wedbush | Reiterates | Outperform | $100 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 4.6% above the 50-day MA ($71.24).
- bullish: Price vs 200-day MA: Trading 5.5% above the 200-day MA ($70.61).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+2.31) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($55.74) and high ($94.11).
IRON Price Chart
Loading chart for IRON…
Fundamentals
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.